このエントリーをはてなブックマークに追加


ID 62296
フルテキストURL
著者
Maruyama, Masato Department of Anatomy and Brain Science, Kansai Medical University
Nakano, Yousuke Department of Anatomy and Brain Science, Kansai Medical University
Nishimura, Takuya Department of Anatomy and Brain Science, Kansai Medical University
Iwata, Ryoichi Department of Neurosurgery, Kansai Medical University
Matsuda, Satoshi Department of Cell Signaling, Institute of Biomedical Science, Kansai Medical University
Hayashi, Mikio Department of Physiology, Kansai Medical University
Nakai, Yuki Department of Anatomy and Brain Science, Kansai Medical University
Nonaka, Masahiro Department of Neurosurgery, Kansai Medical University
Sugimoto, Tetsuo Department of Anatomy and Brain Science, Kansai Medical University
抄録
Glioblastoma multiforme (GBM) is the most prevalent malignant primary brain tumor with a high recurrence rate. Despite multimodal therapy including surgical resection, chemotherapy, and radiotherapy, the median survival time after the initial diagnosis of GBM is approximately 14 months. Since cancer stem cells (CSCs) are considered the leading cause of cancer recurrence, glioblastoma stem cell-targeted therapy is a promising strategy for the treatment of GBM. However, because CSC heterogeneity has been implicated in the difficulties of CSC-target therapy, more in-depth knowledge of CSC biology is still required to develop novel therapies. In this study, we established single cell-derived tumorspheres from human glioblastoma U87MG cells. One of these tumorspheres, P4E8 clone, showed CSC-like phenotypes, such as self-renewal capacity, expression of CSC markers, resistance to anti-cancer agents, and in vivo tumorigenicity. Therefore, we used P4E8 cells as a cell-based model of glioblastoma stem cells (GSCs). Gene expression analysis using microarray indicated that the most highly expressed genes in P4E8 cells compared to the parental U87MG were PC3-secreted microprotein (MSMP). Furthermore, MSMP was expressed in patient-derived GSCs and human glioma tissues at the protein level, implying that MSMP might contribute to glioma development and progression.
発行日
2021-07
出版物タイトル
Biological and Pharmaceutical Bulletin
44巻
7号
出版者
Pharmaceutical Society of Japan
開始ページ
910
終了ページ
919
ISSN
0918-6158
資料タイプ
学術雑誌論文
言語
英語
OAI-PMH Set
岡山大学
著作権者
© 2021 The Pharmaceutical Society of Japan
論文のバージョン
publisher
PubMed ID
DOI
Web of Science KeyUT
関連URL
isVersionOf https://doi.org/10.1248/bpb.b20-00868
助成機関名
Japan Society for the Promotion of Science
Kansai Medical University
助成番号
25460049
17K07183